Fourth COVID-19 vaccine ‘not good enough’ against Omicron: Israeli trial

Click here to read the full article.

A recent preliminary study out of Israel claims that a fourth COVID-19 shot only provided partial protection against the Omicron variant.

While more data is needed, the findings as of now point to an extra booster only seeming worthwhile to age groups far beyond 60, or other high-risk groups.

According to The Times of Israel, a study considered “the first of its kind in the world” concluded that not even a fourth coronavirus vaccine is enough to fully protect against the highly transmissible Omicron variant.

“We see an increase in antibodies, higher than after the third dose. However, we see many infected with Omicron who received the fourth dose. Granted, a bit less than in the control group, but still a lot of infections,” lead researcher Prof. Gili Regev-Yochay said of the findings from the Sheba Medical Center study.

It was back in December 2021 that 154 medical staff at the Sheba facility were injected with a fourth shot for the trial program. While the sample size is significantly smaller than usual trials, these initial findings were presented as soon as possible to the public given the urgency on problem-solving for Omicron.

Continue reading here.

Scroll down for comments and share your thoughts!